AWH (Aspira Women's Health) Multiplikator Forward P/S
The competent management of Aspira Women's Health (AWH) focuses on oncology diagnostics, while the moderate stability of cash flows is based on the volume of laboratory contracts. The business's forward P/S reflects revenue expectations, where the 0.30 level captures the current state. Scaling molecular research optimizes costs, gradually unlocking the company's operating leverage.
Rincian metrik komprehensif lan analitis Aspira Women's Health Inc. (AWH)
- rega pasar lan target rega analis:
- indikator valuasi pasar bisnis:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Rasio Total Utang marang Ekuitas Aspira Women's Health|AWH - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Aspira Women's Health, Inc.|AWH - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Aspira Women's Health Inc|AWH - Utang jangka dawa|Utang jangka cendhak perusahaan Aspira Women's Health|Rasio cepet aspirawh.com
- data bathi bisnis lan rasio investasi:
AWH - Penghasilan resik perusahaan|Bathi sing dikarepake Aspira Women's Health|AWH - Pangali rega marang bathi|Rega marang bathi mangsa ngarep aspirawh.com|AWH - Kapitalisasi marang bathi resik kanthi nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Aspira Women's Health, Inc.|AWH - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Aspira Women's Health|AWH - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan aspirawh.com|AWH - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Aspira Women's Health
- statistik dodolan lan pendapatan perusahaan:
Analisis kabeh metrik perusahaan:AWH (aspirawh.com)
Minimizing fundamental risks requires analyzing the ratio of Aspira Women's Health (AWH) market capitalization to its projected revenue, which allows for an assessment of the premium paid for future growth. This calculation reflects market expectations for the monetization of unique ovarian cancer diagnostic tests, while the company's modeled P/S ratio clearly demonstrates the brand value dynamics from the investors' perspective.
Analisis pesaing
Multiplikator Forward P/S A (agilent.com)|Quest Corp (DGX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ILMN - Rasio rega marang prakiraan pendapatan|EXAS - Multiplikator Forward P/S|RVTY (Revvity) - Multiplikator forward rega marang pendapatan|Bio-Rad - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan anbio.com|Multiplikator Forward P/S Sotera Health Company|Rasio rega marang prakiraan pendapatan QuidelOrtho (QDEL)|OPK - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|caredx.com - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Maravai LifeSciences Corp (MRVI)|FLGT: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan LAB (Fluidigm)|Cytek Biosciences Inc (CTKB) - Rasio rega marang prakiraan pendapatan|OSUR: Rasio rega marang pendapatan sing dikarepake|Multiplikator forward rega marang pendapatan XGN|MDXH: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Lucid Diagnostics Inc. (LUCD)|Rasio rega marang prakiraan pendapatan PRE (Prenetics Global Limited)|Multiplikator Forward P/S IMDX (Insight Molecular Diagnostics Inc)|Rasio rega marang pendapatan sing dikarepake TRIB (Trinity Biotech Corp)|PRPH - Rasio rega marang prakiraan pendapatan|Ainos (AIMD) - Multiplikator forward rega marang pendapatan|CoDx (CODX) - Rasio rega marang prakiraan pendapatan|HSCS (Heart Test Labs) - Rasio rega marang prakiraan pendapatan|BMRA (Biomerica, Inc.) - Multiplikator Forward P/S|CDIO (Cardio Diagnostics) - Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Onconetix Corp (ONCO)|VRAX (Virax Biolabs Group Limited) - Rega forward marang dodolan|Multiplikator Forward P/S BJDX (Bluejay Diagnostics Corp)|Accelerate Diagnostics Inc (AXDX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|centogene.com - Multiplikator Forward P/S|ENZ (Enzo Biochem Inc.) - Kapitalisasi marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep FRES|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GTG Labs (GENE)|ME (23andme.com) - Multiplikator Forward P/S|Multiplikator Forward P/S Psychemedics Inc
